Physician profile
Eric M Kolisz
NPI 1508825175
$2,400.97
in general payments reported to CMS, 2019-2025
22 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $218 · 2021: $502 · 2022: $422 · 2023: $222 · 2024: $140 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,261.56 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Novartis Pharmaceuticals Corporation | $205.90 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $151.29 | 2019-2021 | |
| Sight Sciences, INC. | $135.00 | 2021-2023 | Tearcare System |
| Aerie Pharmaceuticals, INC. | $114.64 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $76.50 | 2025 | Xdemvy |
| Coopervision INC. | $66.40 | 2019-2023 | Myday Contact Lens |
| Abbvie INC. | $58.92 | 2022 | |
| Dompe US, INC. | $54.00 | 2022-2025 | Oxervate |
| Allergan, INC. | $34.88 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $34.56 | 2024 | Purified Cortrophin Gel |
| Abb Con-Cise Optical Group LLC | $25.94 | 2019 | |
| Bausch & Lomb Americas INC. | $24.82 | 2023 | Xiidra |
| Amgen INC. | $24.00 | 2024 | Tepezza |
| Rayner Intraocular Lenses Limited | $21.78 | 2023 | Rayone Spheric, Omidria, Rayone Aspheric |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $21.01 | 2024 | Iyuzeh |
| Optovue, INC. | $19.58 | 2020 | |
| Kala Pharmaceuticals, INC. | $16.88 | 2021 | |
| Ocular Therapeutix, INC. | $15.45 | 2020 | |
| Mallinckrodt Enterprises LLC | $14.78 | 2019 | |
| Sun Pharmaceutical Industries INC. | $12.37 | 2022 | |
| Rxsight INC | $10.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kolisz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.